Portal de Periódicos da CAPES

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

2019; Elsevier BV; Volume: 48; Linguagem: Inglês

10.1016/j.breast.2019.07.006

1532-3080

Marina Elena Cazzaniga, G. Pinotti, Emilia Montagna, D. Amoroso, Rossana Berardi, Alfredo Butera, Katia Cagossi, Luigi Cavanna, Mariangela Ciccarese, Saverio Cinieri, Elisabetta Cretella, E. De Conciliis, Antonio Febbraro, Francesco Ferraù, A. Ferzi, G. Fiorentini, Andrea Fontana, Anna Gambaro, Ornella Garrone, Vittorio Gebbia, Daniele Generali, Luca Gianni, Filippo Giovanardi, A. Grassadonia, V. Leonardi, Paolo Marchetti, Elisabetta Melegari, Antonino Musolino, Mario Nicolini, Carlo Putzu, Ferdinando Riccardi, Daniele Santini, Silvana Saracchini, Maria Giuseppa Sarobba, M. G. Schintu, Giovanni Scognamiglio, P. Spadaro, C. Taverniti, D. Toniolo, Paolo Tralongo, Anna Turletti, Roberto Valenza, Maria Rosaria Valerio, Patrizia Vici, Luca Clivio, Valter Torri, Federica Cicchiello, F. Riva, I. Vallini, Massimiliano Mazza, C. Bonfadini, E. Bordin, Manuela Canicattì, F. Cappuccio, Elena Collovà, C. De Angelis, R. Desorte, Sara Donati, G. Drudi, Daniele Galanti, Carmela Mocerino, Laura Orlando, Benedetta Pellegrino, L. Pizzuti, C. Ridolfi, Andrea Rocca, Donatella Sarti, Ilaria Spagnoletti, Nicola Tinari, Anna Maria Vandone, Loredana Vizzini,

HER2/EGFR in Cancer Research

Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3–10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8–11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3–15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.